human hsp70 cat  (Elabscience Biotechnology)

Journal: Iraqi Journal of Cancer and Medical Genetics

Article Title: Elevated Extracellular Hsp70 Correlates with Increased IL-1 and IL-10 in Iraqi Patients with Colorectal Carcinoma

doi: 10.29409/ijcmg.v16i1.297

Figure Lengend Snippet: Figure 1: Standard curve for (A) Hsp70/Hspa9 (B) IL-1 α (C) IL-10.

Article Snippet: Sandwich ELISA kit obtained from Elabscience, USA (Human Hsp70 Cat. No.: E-EL-H1863, human interleukin 10 Cat. No.: E-EL-H6154 and human interleukin 1 Alpha Cat. No.: E-EL-H0088) were used as per manufacturer recommendations.

Techniques:

Journal: Iraqi Journal of Cancer and Medical Genetics

Article Title: Elevated Extracellular Hsp70 Correlates with Increased IL-1 and IL-10 in Iraqi Patients with Colorectal Carcinoma

doi: 10.29409/ijcmg.v16i1.297

Figure Lengend Snippet: Figure 2: Mean serum level (±SD) of Hsp70 in Iraqi patients with CRC compared to the control. **: p-value ≤ 0.01.

Article Snippet: Sandwich ELISA kit obtained from Elabscience, USA (Human Hsp70 Cat. No.: E-EL-H1863, human interleukin 10 Cat. No.: E-EL-H6154 and human interleukin 1 Alpha Cat. No.: E-EL-H0088) were used as per manufacturer recommendations.

Techniques: Control

Journal: Gut Microbes

Article Title: Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity

doi: 10.1080/19490976.2022.2117503

Figure Lengend Snippet: P144 binding mAbs isolated from naïve SPF mice reacted with commensal gut bacteria from both human and mouse . Reactivities between P144 binding mAbs and gut microbial antigens were detected using WB assays. A purified mouse IgG was used as the control. (a) WB assays of mouse fecal bacteria samples. L: mixed fecal bacteria samples collected from 3 mice with low levels of preexisting S2 binding antibodies (OD 450nm-630nm ≤0.140, 1:100 diluted); H: mixed fecal bacteria samples collected from 3 mice with high levels of preexisting S2 binding antibodies (OD 450nm-630nm ≥0.615, 1:100 diluted). (b) WB assays of fecal bacteria samples collected from 7 healthy individuals (Lanes 1–7). All the mAbs and the control mouse IgG were tested at the final concentration of 1 μg/ml. Black arrows indicate the locations of protein bands selected for the mass spectrometry analysis. (c) Reactivity between a P144 specific mAb (clone F5) and E. coli was validated by WB. F5 or a purified mouse IgG was used as the first antibody at the concentration of 1 μg/ml. Black arrows point out the bands with MWs equal to E. coli proteins identified by LC-MS analysis. (d) Recognition of purified E. coli HSP60 protein by P144 reactive antibodies. (e) Recognition of purified E. coli HSP70 protein by P144 reactive antibodies. All the mAbs and control IgG were measured at a final concentration of 10 μg/ml. Dotted line represents the mean OD value of control IgG plus 2-fold SD (mean+2SD).

Article Snippet: High-binding 96-well EIA plates (Cat# 9018, Corning, USA) were coated with purified SARS-CoV-2 S1 (Cat# 40591-V08H, Sino Biological, China), S2 proteins (Cat# 40590-V08B, Sino Biological, China), recombinant E. coli HSP60 (Cat#HSP-004, Prospec, Jsrael), E. coli HSP70 (Cat#HSP-006, Prospec, Jsrael), human HSP60 (Cat#HSP-016, Prospec, Jsrael) or human HSP70 (Cat#HSP-170, Prospec, Jsrael) at a final concentration of 1 μg/ml in carbonate/bi-carbonate coating buffer (30 mM NaHCO 3 ,10 mM Na 2 CO 3 , pH 9.6).

Techniques: Binding Assay, Isolation, Bacteria, Purification, Control, Concentration Assay, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy